Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: 2-5A antisense compounds - IFN

Drug Profile

Research programme: 2-5A antisense compounds - IFN

Alternative Names: MP 351; NIH 351; spA4-anti-hTr

Latest Information Update: 23 Apr 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); The Cleveland Clinic Foundation
  • Developer IFN
  • Class Antivirals
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; RNA inhibitors; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Respiratory syncytial virus infections
  • Discontinued Acne; Alopecia

Most Recent Events

  • 05 May 2001 Gemini has sold all of its assets relating to 2-5A antisense technology to IFN
  • 31 Dec 2000 Discontinued - Preclinical for Acne in USA (unspecified route)
  • 31 Dec 2000 Discontinued - Preclinical for Alopecia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top